Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323289 | 0.86 | ERCC1 (0.41) | AKR1B1ERCC1ERCC4P2RX7DAO | |
| SCHEMBL4320213 | 0.84 | ERCC1 (0.39) | AKR1B1ERCC1ERCC4 | |
| SCHEMBL4153042 | 0.83 | RAB9A (0.46) | KCNH2AKR1B1LMNATP53 | |
| SCHEMBL4320121 | 0.81 | ERCC1 (0.48) | KCNH2ERCC1ERCC4EGLN1P2RX7 | |
| SCHEMBL4330995 | 0.81 | ERCC1 (0.42) | KCNH2AKR1B1ERCC1ERCC4P2RX7 | |
| SCHEMBL13892419 | 0.81 | ERCC1 (0.38) | KCNH2AKR1B1ERCC1ERCC4P2RX7 | |
| SCHEMBL4318984 | 0.80 | P2RX7 (0.49) | MAPK3MAPK1KCNH2ERCC1ERCC4 | |
| SCHEMBL14129745 | 0.80 | DRD3 (0.43) | KCNH2ERCC1ERCC4TP53 | |
| SCHEMBL4315216 | 0.79 | CYP2D6 (0.47) | MAPK1KCNH2EGLN1LMNATP53 | |
| Hydrochloric Acid SCHEMBL4321399 | 0.79 | DRD3 (0.42) | KCNH2ERCC1ERCC4LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161639-A1 | Hiv integrase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-07-12 | — | — | US | claimed |
| US-20090099168-A1 | HIV Integrase inhibitors | DONGHI MONICA | 2009-04-16 | — | — | US | disclosed |
| US-20090099168-A1 | HIV Integrase inhibitors | DONGHI MONICA | 2009-04-16 | — | — | US | disclosed |
| US-20070161639-A1 | Hiv integrase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-07-12 | — | — | US | disclosed |
| US-20070161639-A1 | Hiv integrase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-07-12 | — | — | US | disclosed |
| US-20070161639-A1 | Hiv integrase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161639-A1 | Hiv integrase inhibitors | DPYD, DUT, TYMP | MAPK3 1758/4885MAPK1 1569/4885KCNH2 666/4885 |
| US-20090099168-A1 | HIV Integrase inhibitors | DPYD, DUT, QDPR | MAPK3 1570/4885MAPK1 1269/4885KCNH2 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.